Britain’s second-biggest drugmaker has rejected a $106 billion approach from its U.S. rival Pfizer, arguing that it has a bright future as an independent firm due to a promising pipeline of cancer and other drugs. Its new lung cancer drug, known as AZD9291, targets a genetic mutation that helps tumors evade current treatments. AstraZeneca believes it could sell as much as $3 billion a year.